-
RareAction Network > Peter L. Saltonstall
Archives
1-8 of 8 items
Rare Disease Advocates Host a Save the Orphan Drug Tax Credit Rally
November 28, 2017
Patients speak out as Congress moves forward with a tax bill that would negatively impact individuals with rare diseases Washington, D.C., November 28, 2017 – Today, the National Organization for Rare Disorders (NORD) is hosting a Save the Orphan Drug Tax Credit Rally for the rare disease community in response to the tax reform bill being debated in […]
$1.1 Billion in Federal Funding to Fight the Zika Virus
September 29, 2016
Washington, D.C., September 29, 2016 – The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, released the following statement from President and CEO Peter L. Saltonstall following President Obama’s signature of the Continuing Resolution today. “On behalf of the 30 million Americans with rare diseases, […]
September 23, 2016
Unanimous vote extends the Rare Pediatric Disease Priority Review Voucher Program with important policy changes through December Washington, D.C., September 23, 2016 – On Thursday, the Senate reached an important compromise to accelerate new treatments to help 15 million sick children with rare diseases. Led by Senators Robert Casey (D-PA), Johnny Isakson (R-GA), and Lamar Alexander […]
The Hill publishes NORD op-ed: Congress must act now to help 15 million sick children
September 15, 2016
The Hill, a top U.S. political website, read by Congressional offices, the White House, political pundits, and more, today published the following op-ed by NORD President and CEO, Peter L. Saltonstall, urging Congress to reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) program. The PRV program encourages the development of therapies for children with […]
NORD Responds to AHIP Report on Orphan Drug Act
September 2, 2016
By Peter L. Saltonstall One of the most successful pieces of legislation ever passed by the Congress is the Orphan Drug Act of 1983 (ODA). It was intended to stimulate the research and development of new therapies for rare diseases, which were generally neglected by the research community and the drug industry. Since 1983, more […]
NORD Issues Statement as Senate Postpones Vote on Cures Legislation
July 14, 2016
The following statement was issued by Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), as the Senate announced it would not vote on its Cures legislation, also known as the Senate Innovations for Healthier Americans Initiative, until September at the very earliest. “On behalf of the 1 in 10 […]
Impact of the Orphan Drug Tax Credit for Rare Diseases
June 17, 2015
Today, the National Organization for Rare Disorders (NORD), Biotechnology Industry Organization (BIO), and Ernst & Young released “Impact of the Orphan Drug Tax Credit on Treatments for Rare Diseases,” a new white paper examining the role of the Orphan Drug Tax Credit (ODTC) on rare disease drug discovery. Patients share their experiences in profiles that […]
NORD Issues Statement on Today’s Approval of the 21st Century Cures Initiative
May 21, 2015
NORD President and CEO Peter L. Saltonstall today issued the following statement on the approval by the House Energy and Commerce Committee of the 21st Century Cures legislative initiative and the introduction of the OPEN Act in the United States Senate. NORD congratulates the House Energy and Commerce Committee for unanimously approving the 21st Century […]
1-8 of 8 items
Quick Search
Subscribe
Blog Categories
Archives